Differential expression and processing of secretogranin ii in relation to the status of pheochromocytoma: Implications for the production of the tumoral marker EM66

Journal of Molecular Endocrinology

Volumn 48, Issue 2, 2012, Pages 115-127

  Guillemot, J ^a,e   Thouennon E ^a   Guerin M ^a   Vallet Erdtmann, V ^b   Ravni, A ^a   Montero Hadjadje M ^a   Lefebvre, H ^a   Klein, M ^c   Muresan, M ^d   Seidah, N G ^e   Anouar, Y ^a   Yon, L ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c CHU NANCY BRABOIS   (France)

^d Bon Secours Hospital   (France)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; SECRETOGRANIN II; TUMOR MARKER;

ADOLESCENT; ADRENAL GLAND; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHEOCHROMOCYTOMA; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; SECRETOGRANIN II; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84858817664     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-11-0077     Document Type: Article

References (60)

1. Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK & Singh U 2010 Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World Journal of Surgery 34 3022-3028. (doi:10.1007/s00268-010-0744-5)
2. Anouar Y, Jegou S, Alexandre D, Lihrmann I, Conlon JM & Vaudry H 1996 Molecular cloning of frog secretogranin II reveals the occurrence of several highly conserved potential regulatory peptides. FEBS Letters 394 295-299. (doi:10.1016/0014-5793(96)00976-3)
3. Anouar Y, Yon L, Desmoucelles C, Leprince J, Breault L, Gallo-Payet N.& Vaudry H 1998 Identification of a novel secretogranin II-derived peptide in the adult and fetal human adrenal gland. Endocrine Research 24 731-736. (doi:10.3109/07435809809032678)
4. Benjannet S, Rondeau N, Paquet L, Boudreault A, Lazure C, Chretien M, Seidah NG 1993 Comparativebiosynthesis,covalentpost-translational modifications and efficiency of prosegment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of prosegment cleavage of PC1 and PC2. Biochemical Journal 294 735-743.
5. Boutahricht M, Guillemot J, Montero-Hadjadje M, Bellafqih S, El Ouezzani S, Alaoui A, Yon L, Vaudry H, Anouar Y & Magoul R 2005 Biochemical characterisation and immunohistochemical local-isation of the secretogranin II-derived peptide EM66 in the hypothalamus of the jerboa (Jaculus orientalis): modulation by food deprivation. Journal of Neuroendocrinology 17 372-378. (doi:10.1111/j.1365-2826.2005.01314.x)
6. Boutahricht M, Guillemot J, Montero-Hadjadje M, Barakat Y, El Ouezzani S, Alaoui A, Yon L, Vaudry H, Anouar Y & Magoul R 2007 Immunohistochemical distribution of the secretogranin II-derived peptide EM66 in the rat hypothalamus: a comparative study with jerboa. Neuroscience Letters 414 268-272. (doi:10.1016/j.neulet.2006.12.033)
7. Chomczynski P & Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162 156-159. (doi:10.1016/0003-2697(87)90021-2)
8. Chrisoulidou A, Kaltsas G, Ilias I & Grossman AB 2007 The diagnosis and management of malignant phaeochromocytoma and para-ganglioma Endocrine-Related Cancer 14 569-585. (doi:10.1677/ERC-07-0074)
9. Colombo B, Curnis F, Foglieni C, Monno A, Arrigoni G & Corti A 2002 Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Research 62 941-946.
10. Conlon JM 2010 Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors. Regulatory Peptides 165 5-11. (doi:10.1016/j.regpep.2009.11.013)
11. Dittie AS & Tooze SA 1995 Characterization of the endopeptidase PC2 activity towards secretogranin II in stably transfected PC12 cells. Biochemical Journal 310 777-787.
12. Eder U, Fischer-Colbrie R, Kogner P, Leitner B, Bjellerup P & Winkler H 1998 Levels and molecular forms of chromogranins in human childhood neuroblastomas and ganglioneuromas. Neuroscience Letters 253 17-20. (doi:10.1016/S0304-3940(98)00588-6)
13. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ et al. 2011 Plasma methoxytyramine: a novel biomarker of metastatic www.endocrinology-journals.org pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer. (doi:10.1016/j.ejca.2011.07.016)
14. Fischer-Colbrie R, Laslop A & Kirchmair R 1995 Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Progress in Neurobiology 46 49-70. (doi:10.1016/0301-0082(94)00060-U)
15. Fischer-Colbrie R, Kirchmair R, Kahler CM, Wiedermann CJ & Saria A 2005 Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system Current Protein & Peptide Science 6 373-385. (doi:10.2174/13892030 54546334)
16. Gao B, Meng F, Bian W, Chen J, Zhao H, Ma G, Shi B, Zhang J, Liu Y & Xu Z 2006 Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 68 282-286. (doi:10.1016/j.urology.2006.02.019)
17. Guerin M, Guillemot J, Thouennon E, Pierre A, El-Yamani FZ, Montero-Hadjadje M, Dubessy C, Magoul R, Lihrmann I, Anouar Y et al. 2010 Granins and their derived peptides in normal and tumoral chromaffin tissue: implications for the diagnosis and prognosis of pheochromocytoma. Regulatory Peptides 165 21-29. (doi:10.1016/j.regpep.2010.06.003)
18. Guillemot J, Anouar Y, Montero-Hadjadje M, Grouzmann E, Grumolato L, Roshmaninho-Salgado J, Turquier V, Duparc C, Lefebvre H, Plouin PF et al. 2006 Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromo-cytoma. International Journal of Cancer 118 2003-2012. (doi:10.1002/ ijc.21571)
19. Hoflehner J, Eder U, Laslop A, Seidah NG, Fischer-Colbrie R & Winkler H 1995 Processing of secretogranin II by prohormone convertases: importance of PC1 in generation of secretoneurin. FEBS Letters 360 294-298. (doi:10.1016/0014-5793(95)00127-U)
20. Ischia R, Gasser RW, Fischer-Colbrie R, Eder U, Pagani A, Cubeddu LX, Lovisetti-Scamihorn P, Finkenstedt G, Laslop A & Winkler H 2000a Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. Journal of Clinical Endocrinology and Metabolism 85 355-360. (doi:10.1210/jc.85.1.355)
21. Ischia R, Hobisch A, Bauer R, Weiss U, Gasser RW, Horninger W, Bartsch G Jr, Fuchs D, Bartsch G, Winkler H et al. 2000b Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. Journal of Urology 163 1161-1164. (doi:10.1016/S0022-5347(05)67714-2)
22. Kantorovich V & Pacak K 2010 Pheochromocytoma and paraganglioma. Progress in Brain Research 182 343-373. (doi:10.1016/S0079-6123(10)82015-1)
23. Karasek D, Frysak Z & Pacak K 2010 Genetic testing for pheochromocytoma. Current Hypertension Reports 12 456-464. (doi:10.1007/s11906-010-0151-1)
24. Konoshita T, Gasc JM, Villard E, Takeda R, Seidah NG, Corvol P & Pinet F 1994 Expression of PC2 and PC1/PC3 in human pheochromocytomas. Molecular and Cellular Endocrinology 99 307-314. (doi:10.1016/0303-7207(94)90022-1)
25. Laslop A, Weiss C, Savaria D, Eiter C, Tooze SA, Seidah NG & Winkler H 1998 Proteolytic processing of chromogranin B and secreto-granin II by prohormone convertases. Journal of Neurochemistry 70 374-383. (doi:10.1046/j.1471-4159.1998.70010374.x)
26. Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnima-laiyaan M, Chen H, Westin G, Sandgren J, Stalberg P, Khanafshar E et al. 2010 MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocrine-Related Cancer 17 835-846. (doi:10.1677/ERC-10-0142)
27. Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK & Anouar Y 2008 Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiologica 192 309-324. (doi:10.1111/j.1748-1716.2007.01806.x)
28. Muller L & Tougard C 1995 Production and secretion of N-terminal secretogranin II derived peptides in GH3B6 prolactin cells. Molecular and Cellular Endocrinology 112 101-112. (doi:10.1016/ 0303-7207(95)03594-W)
29. Pagani A, Forni M, Tonini GP, Papotti M & Bussolati G 1992 Expression of members of the chromogranin family in primary neuroblastomas. Diagnostic Molecular Pathology 1 16-24. (doi:10. 1097/00019606-199203000-00003)
30. Papewalis C, Kouatchoua C, Ehlers M, Jacobs B, Porwol D, Schinner S, Willenberg HS, Anlauf M, Raffel A, Eisenhofer G et al. 2011 Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma. Molecular and Cellular Endocrinology 33569-77. (doi:10.1016/j.mce.2010.05.021)
31. Peinado JR, Vazquez-Martinez R, Cruz-Garcia D, Ruiz-Navarro A, Anouar Y, Tonon MC, Vaudry H, Gracia-Navarro F, Castano JP Malagon MM 2006 Differential expression and processing of chromogranin A and secretogranin II in relation to the secretory status of endocrine cells Endocrinology 147 1408-1418. (doi:10. 1210/en.2005-0975)
32. Portela-Gomes GM, Stridsberg M, Grimelius L, Falkmer UG & Falkmer S 2004 Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas. An immunohistochemical study with regionspecific antibodies. APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica 112 663-673. (doi:10.1111/j.1600-0463. 2004.t01-1-apm1121005.x)
33. Portela-Gomes GM, Grimelius L, Wilander E & Stridsberg M 2010 Granins and granin-related peptides in neuroendocrine tumours. Regulatory Peptides 165 12-20. (doi:10.1016/j.regpep. 2010.02.011)
34. Rosa P & Gerdes HH 1994 The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. Journal of Endocrinological Investigation 17 207-225.
35. 0-monophosphate-responsive elementbinding protein (CREB) is decreased during human adrenal cortex tumorigenesis and fetal development. Journal of Clinical Endocrinology and Metabolism 88 3958-3965. (doi:10.1210/jc.2003-030070)
36. Scammell JG, Reddy S, Valentine DL, Coker TN, Nikolopoulos SN & Ross RA 2000 Isolation and characterization of the human secretogranin II gene promoter. Brain Research. Molecular Brain Research 75 8-15. (doi:10.1016/S0169-328X(99)00269-7)
37. Schober M, Fischer-Colbrie R, Schmid KW, Bussolati G, O'Connor DT & Winkler H 1987 Comparison of chromogranins A, B, and secretogranin II in human adrenal medulla and pheochromocytoma. Laboratory Investigation 57 385-391.
38. Scopsi L, Gullo M, Rilke F, Martin S & Steiner DF 1995 Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. Journal of Clinical Endocrinology and Metabolism 80 294-301. (doi:10. 1210/jc.80.1.294)
39. Shyu WC, Lin SZ, Chiang MF, Chen DC, Su CY, Wang HJ, Liu RS, Tsai CH & Li H 2008 Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. Journal of Clinical Investigation 118 133-148. (doi:10.1172/ JCI32723)
40. Song SB, Rhee M, Roberson MS, Maurer RA & Kim KE 2003 Gonadotropin-releasing hormone-induced stimulation of the rat secretogranin II promoter involves activation of CREB. Molecular and Cellular Endocrinology 199 29-36. (doi:10.1016/S0303-7207(02)00334-9)
41. Stridsberg M, Eriksson B & Janson ET 2008 Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regulatory Peptides 148 95-98. (doi:10.1016/j.regpep.2008.03.007)
42. Suh I, Shibru D, Eisenhofer G, Pacak K, Duh QY, Clark OH & Kebebew E 2009 Candidate genes associated with malignant pheochromo-cytomas by genome-wide expression profiling. Annals of Surgery 250 983-990. (doi:10.1097/SLA.0b013e3181b248bb)
43. Tano K, Oyabu A, Tashiro Y, Kamada N, Narita N, Nasu F & Narita M 2010 Manserin, a secretogranin II-derived peptide, distributes in the rat endocrine pancreas colocalized with islet-cell specific manner. Histochemistry and Cell Biology 134 53-57. (doi:10.1007/ s00418-010-0709-7)
44. Thompson LD 2002 Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. American Journal of Surgical Pathology 26 551-566. (doi:10.1097/ 00000478-200205000-00002)
45. Thouënnon E, Elkahloun AG, Guillemot J, Gimenez-Roqueplo AP, Bertherat J, Pierre A, Ghzili H, Grumolato L, Muresan M, Klein M et al. 2007 Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. Journal of Clinical Endocrinology and Metabolism 92 4865-4872. (doi:10.1210/jc. 2007-1253)
46. Thouënnon E, Pierre A, Guillemot J, Yon L, Eisenhofer G & Anouar Y 2009 Genetic markers for the diagnosis and prognosis of pheochromocytoma. Expert Review of Endocrinology & Metabolism 4 45-52. (doi:10.1586/17446651.4.1.45)
47. Thouënnon E, Pierre A, Tanguy Y, Guillemot J, Manecka DL, Guerin M, Ouafik L, Muresan M, Klein M, Bertherat J et al. 2010 Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival. Endocrine-Related Cancer 17 637-651. (doi:10.1677/ERC-10-0109)
48. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, Pacak K & Lenders JW 2008 Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocrine-Related Cancer 15 1127-1133. (doi:10.1677/ERC-08-0049)
49. Turquier V, Yon L, Grumolato L, Alexandre D, Fournier A, Vaudry H & Anouar Y 2001 Pituitary adenylate cyclase-activating polypeptide stimulates secretoneurin release and secretogranin II gene transcription in bovine adrenochromaffin cells through multiple signaling pathways and increased binding of pre-existing activator protein-1-like transcription factors. Molecular Pharmacology 6042-52.
50. Vallet VS, Griffond B, Clavequin MC, de Monti M, Fellmann D & Duval J 1995 Early detection of secretogranin-II (SgII) in the human fetal pituitary: immunocytochemical study using an antiserum raised against a human recombinant SgII. Endocrinology 136 2074-2081. (doi:10.1210/en.136.5.2074)
51. Vallet VS, Li JY & Duval J 1997 Secretogranin II (SgII) distribution and processing studies in human normal and adenomatous anterior pituitaries using new polyclonal antibodies. Regulatory Peptides 68 155-163. (doi:10.1016/S0167-0115(96)02110-6)
52. Van Horssen AM & Martens GJ 1999 Biosynthesis of secretogranin II in Xenopus intermediate pituitary. Molecular and Cellular Endocrinology 14757-64. (doi:10.1016/S0303-7207(98)00219-6)
53. Waldmann J, Fendrich V, Holler J, Buchholz M, Heinmoller E, Langer P, Ramaswamy A, Samans B, Walz MK, Rothmund M et al. 2010 Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocrine-Related Cancer 17 743-756. (doi:10.1677/ERC-09-0118)
54. Winkler H & Fischer-Colbrie R 1992 The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49 497-528. (doi:10.1016/0306-4522(92)90222-N)
55. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F&Nose V 2009Observervariationintheapplicationofthe pheochromocytoma of the adrenal gland scaled score. American Journal of Surgical Pathology 33 599-608. (doi:10.1097/PAS.0b013e318190d12e)
56. Yajima A, Ikeda M, Miyazaki K, Maeshima T, Narita N & Narita M 2004 Manserin, a novel peptide from secretogranin II in the neuro-endocrine system. Neuroreport 15 1755-1759. (doi:10.1097/01.wnr. 0000127634.38052.84)
57. Yajima A, Narita N & Narita M 2008 Recently identified a novel neuropeptide manserin colocalize with the TUNEL-positive cells in the top villi of the rat duodenum. Journal of Peptide Science 14773-776. (doi:10.1002/psc.991)
58. Yon L, Guillemot J, Montero-Hadjadje M, Grumolato L, Leprince J, Lefebvre H, Contesse V, Plouin PF, Vaudry H & Anouar Y 2003 Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. Journal of Clinical Endocrinology and Metabolism 88 2579-2585. (doi:10.1210/jc.2002-021748)
59. Zhao E, Basak A, Crump K & Trudeau VL 2006 Proteolytic processing and differential distribution of secretogranin-II in goldfish. General and Comparative Endocrinology 146 100-107. (doi:10.1016/j.ygcen. 2005.10.007)
60. Zhao E, Hu H & Trudeau VL 2010 Secretoneurin as a hormone regulator in the pituitary. Regulatory Peptides 165 117-122. (doi:10.1016/j.regpep.2009.11.019)